pharma industry

Neuroscience these days

My earlier mentioned participation in the ‘Good life better‘ workshop in October will hopefully help me develop a good paper for the conference “Neurosociety… What is it with brains these days?” to be held at the Saïd Business School, University of Oxford, in December. They have just accepted my abstract (see earlier post), and I’m […]


My earlier mentioned participation in the ‘Good life better‘ workshop in October will hopefully help me develop a good paper for the conference “Neurosociety… What is it with brains these days?” to be held at the Saïd Business School, University of Oxford, in December. They have just accepted my abstract (see earlier post), and I’m looking very much forward to participating.
As the conference website states:

The last twenty years have seen unprecedented advances in the neurosciences, in fields such as psychopharmacology, neurology and behavioural genetics. A growing number of ethicists, social scientists, legal scholars and philosophers have begun to analyze the social, legal and ethical implications of these advances, from the use of fMRI imaging in legal cases, to the medical benefits and risks of the increasing prescription of psychotropic drugs such as Prozac and Ritalin. Some attention has been paid to the economic questions raised by the commercial development and application of new technologies, and the extent to which subfields such as neuroeconomics and neuromarketing are generating commercially and clinically valuable findings. The conference aims to bring together academics and practitioners from this wide range of disciplines to attempt a critical evaluation of the current state and future prospects for neuro thinking.

The neurosciences are really at the centre of attention these days!